Centre National De La Recherche Scientifique

UniversitÉde Strasbourg

Quimica Sintetica, S.a.

Chemo Research, S.l.

Chemo Iberica, S.a.

Sigma-tau Research Switzerland S.a.

Maurizio Taddei

André Mann

Martial Ruat

Hélène Faure

Marcello Rasparini

Fabrizio Manetti

Luca Carcone

Antonio Solinas

Angèle Schoenfelder

Elena Cini

Angele Schoenfelder

Giuseppe Barreca

Elisabeth Traiffort

Giovanni Marras

Hermine Roudaut

Walter Cabri

Claudio Pisano

Giuseppe Giannini

Antonio Zanotti-Gerosa

Loredana Vesci

Damian Mark Grainger

Stephen James Roseblade

Tatiana Gorojankina

Roberto Rocco Tufaro

Claudio Cianferotti

Samantha Louise Staniland

Lucile Hoch

Andrea Poggiali

Serena Ferrini

Maria Luisa Cervoni

Romina Vitale

Luca Banfi

Renata Riva

Adele Russo

Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process. 

Process for the preparation of sphingosine-1-phosphate receptor agonist

Two processes are described for preparing, in different diastereomeric purity degrees, the compound (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)-phosphoryl)amino) propanoate, having the formula given below, known as Sofosbuvir and used for the treatment of hepatitis C. 

Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof

The invention relates to a process for the synthesis of Cariprazine, an antipsychotic compound useful in the treatment of positive and negative symptoms associated to schizophrenia, with the following structural formula: (A) The invention further relates to the synthesis of intermediates useful in the preparation of Cariprazine. 

1,4-cyclohexylamine derivatives and processes for the preparation thereof

A new route of synthesis of the compound Aliskiren of formula (I), used in the treatment of hypertension, is described. 

Process for producing Aliskiren

The present invention relates to aryl triazole derivatives of Formula I having antitumoural activity through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical composition containing such compounds. 

Aryl triazole compounds with antitumoural activity

The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.

N-acylthiourea and N-acylurea inhibitors of the Hedgehog protein signalling pathway

The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same. 

Quinolinone derivatives

The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I). The invention also relates to a method for radio-marking compounds having formula (I), the marked compounds, and the use of the compounds as research tools, and method for screening and/or identifying ligands in the Smoothened receptor (Smo) binding sites, methods for identifying agonists and antagonists of the Smoothened receptor, and a method for identifying cells.

Compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications

The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.

Acyl guanidine derivatives modulating the hedgehog protein signaling pathway

Growing community of inventors

Monteriggioni, Italy

Maurizio Taddei